Theravance Biopharma, Inc. (NASDAQ: TBPH)

Theravance Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines targeting respiratory and other chronic diseases. The company’s primary commercial product, YUPELRI, is an FDA-approved once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease. Theravance Biopharma operates in a highly regulated industry, leveraging partnerships and royalty arrangements to drive revenue while managing a lean operational structure centered on outsourced manufacturing and research activities.

The company generates revenue through product sales, profit-sharing agreements, royalties, and milestone payments. Its flagship product, YUPELRI, contributes directly to revenue via a profit-sharing arrangement with commercial partner Viatris Inc., where Theravance Biopharma retains a 35% share of net profits. Additionally, the company earns royalties from global net sales of TRELEGY, a triple-therapy inhaler developed by GSK, though it sold its remaining royalty interest in 2025 while retaining rights to potential milestone payments. Other revenue streams include upfront payments, regulatory milestones, and licensing fees tied to developmental programs and partnerships.

The company operates through the following segments.

• Commercial Products. This segment centers on YUPELRI, a once-daily nebulized therapy for COPD patients who require or prefer nebulized delivery. The product is co-promoted in the U. S. under a profit-sharing agreement with Viatris, while international rights (excluding China) are licensed to Viatris in exchange for tiered royalties. Theravance Biopharma retains rights to alternative dosage forms, such as metered-dose and dry powder inhalers, for future development.

• Royalty and Milestone Interests. The company holds economic interests in external products, primarily TRELEGY, a once-daily triple-therapy inhaler for COPD and asthma marketed by GSK. Though Theravance Biopharma sold its remaining royalty interest in 2025, it retains rights to receive up to $150 million in milestone payments tied to future sales thresholds. Additional milestone payments are linked to regulatory and commercial achievements in China and other international markets.

• Research and Development. Historically, this segment focused on advancing internal pipeline candidates, including ampreloxetine, a norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension in multiple system atrophy patients. Following the failure of its Phase 3 CYPRESS study in 2026, the company decided to wind down the ampreloxetine program and is restructuring to eliminate most R&D activities, reallocating resources toward commercial operations.

Theravance Biopharma occupies a niche position within the respiratory therapeutics market, competing in a landscape dominated by larger pharmaceutical companies with broader portfolios and commercial infrastructures. Its competitive advantage lies in YUPELRI’s unique once-daily nebulized formulation, addressing an underserved segment of COPD patients who cannot or prefer not to use handheld inhalers. The product benefits from strong intellectual property protection, with Orange Book-listed patents extending into the late 2030s, and a settled patent litigation strategy that delays generic competition until 2039. However, the company faces competition from alternative therapies, including IL-4/IL-13 and IL-5 monoclonal antibodies, as well as emerging nebulized treatments like Merck’s Ohtuvayre. Its reliance on partnerships, particularly with Viatris and GSK, exposes it to execution risks tied to third-party commercialization efforts.

The company’s customer base primarily consists of COPD patients in the U. S. and international markets, with prescriptions driven by pulmonologists, primary care physicians, and respiratory therapists. YUPELRI is distributed through pharmacies and healthcare providers specializing in nebulized therapies, while TRELEGY’s customer base includes both COPD and asthma patients globally. Specific customer names are not disclosed, but the company’s revenue is derived from partnerships with pharmaceutical distributors, insurers, and government payors, including Medicare and Medicaid in the U. S.